Navigation Links
Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:8/3/2010

NORTHBROOK, Ill., Aug. 3 /PRNewswire/ -- Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by the Company.

Jefferies & Company, Inc. and Piper Jaffray & Co. are acting as joint book-running managers, and JMP Securities LLC and Lazard Capital Markets LLC are acting as co-managers for the offering.  The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to the offering may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022 or at (877) 547-6340.

A registration statement related to these securities has been filed with the SEC, but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Horizon Pharma

Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.  


'/>"/>
SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
2. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
3. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
10. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... early toxicology and efficacy studies. The company is harnessing ... specific protein, MAGE A, in an effort to find ... After 4 weeks of treatment in transgenic ... little toxicity in a full toxicology report of various ...
(Date:3/27/2017)... , March 27, 2017 To mark the end ... , Inc., a leader in digital imaging solutions, will showcase ... convention, held at New York,s Jacob ... Your Vision Month, sponsored by the American Optometric Association, is ... importance of receiving comprehensive eye exams. In recognition of this ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts ... is legal will generate $655 million in taxes on retail sales. ... taxes, such as Washington State,s 37% cannabis ... state sales taxes that are applied on all retail sales. By ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who ... 8-10. , This event was exclusive to providers and offered an opportunity to ... took place at the Manchester Grand Hyatt where attendees gathered for a lively discussion ...
(Date:3/28/2017)... ... March 28, 2017 , ... Bacteria and fungi are probably not the first ingredients that come ... including the right microorganisms in your diet can actually improve health outcomes. And the good ... is the topic of a new peer-reviewed paper led by Maria Marco, ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... containerization, today announced it will co-exhibit with technology partners LG Business Solutions at ... the Marriott Metro Center in Washington D.C., will provide education and examination into ...
Breaking Medicine News(10 mins):